Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Elevated serum levels of Acid sphingomyelinase in female patients with episodic and chronic migraine

  • Ouro Villasante, Alberto
  • Castro Mosquera, Mónica
  • Rodríguez Arrizabalaga, Mariña
  • Debasa Mouce, Manuel
  • Custodia, Antía
  • Aramburu Núñez, Marta
  • Romaus-Sanjurjo, Daniel
  • Casas, Josefina
  • Lema Gesto, María Isabel
  • Castillo, José
  • Leira Muiño, Rogelio
  • Sobrino Moreiras, Tomás
Migraine is one of the most common neurological disorders and the second most disabling human condition. The molecular mechanisms of migraine have been linked to neuropeptide release, endothelial dysfunction, oxidative stress and inflammatory processes. Acid sphingomyelinase (aSMase) is a secreted enzyme that leads to sphingomyelin degradation to produce ceramide. Its activity has been associated with several molecular processes involved in migraine. Therefore, this cross-sectional study aims to study the potential role of aSMase in patients with episodic and chronic migraine. In this cross-sectional pilot study, serum samples from female healthy controls (n = 23), episodic migraine (EM) patients (n = 31), and chronic migraine (CM) patients (n = 28) were studied. The total serum levels of aSMase were determined by ELISA. In addition, the serum levels of sphingomyelin (SM), dihydro-sphingomyelin (dhSM), ceramide (Cer), and dihydro-ceramide (dhCer) were determined by mass spectrometry as biomarkers involved in the main molecular pathways associated with aSMase. aSMase serum levels were found significantly elevated in both EM (3.62 ± 1.25 ng/mL) and CM (3.07 ± 0.95 ng/mL) compared with controls (1.58 ± 0.72 ng/mL) (p < 0.0001). ROC analysis showed an area under the curve (AUC) of 0.94 (95% CI: 0.89–0.99, p < 0.0001) and 0.90 (95% CI: 0.81–0.99, p < 0.0001) for EM and CM compared to controls, respectively. Regarding other biomarkers associated with aSMase’s pathways, total SM serum levels were significantly decreased in both EM (173,534 ± 39,096 pmol/mL, p < 0.01) and CM (158,459 ± 40,010 pmol/mL, p < 0.0001) compared to the control subjects (219,721 ± 36,950 pmol/mL). Elevated serum levels of aSMase were found in EM and CM patients compared to the control subjects. The decreased SM levels found in both EM and CM indicate that aSMase activity plays a role in migraine. Therefore, aSMase may constitute a new therapeutic target in migraine that should be further investigated.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Intracerebroventricular phospho-tau immunotherapy alleviates cortical phospho-tau burden and motor phenotype in a neuron-specific P301S tauopathy mouse

  • Kemppainen, S.
  • Aramburu-Núñez, M.
  • Koivisto, H.
  • Posado-Fernández, A.
  • Felix-Garcia, M. R.
  • Nurminen, K.
  • Häkli, S.
  • Abelli-Deulofeu, E.
  • Kaisto, M.
  • Custodia, A.
  • van Olst, L.
  • Willman, R-M
  • Mäkinen, P.
  • Miettinen, P. O.
  • Schouten, M.
  • Iglesias-Rey, Ramón
  • Kamermans, A.
  • Martiskainen, H.
  • Rauramaa, T.
  • de Vries, H. E.
  • Eng, E.
  • Salo, R.
  • Kettunen, M.
  • Gröhn, O.
  • Gureviciene, I.
  • Chmielevski, P.
  • Ouro, A.
  • Lapresa, Rebeca
  • Agulla, Jesús
  • Almeida, Angeles
  • Doria, G.
  • Flores, O.
  • Aguiar, P.
  • Carmans, S.
  • Roucourt, B.
  • Hiltunen, M.
  • Sobrino, T.
  • Tanila, H.
Pathological tau accumulation disrupts neuronal function, leading to neurodegeneration and dementia in tauopathies, such as Alzheimer's disease and frontotemporal dementia. Despite the progression of several anti-tau therapies to clinical trials, no disease-modifying treatments for tauopathies exist. Tau hyperphosphorylation is a key factor in pathology progression. Among all tau phosphorylation sites targeted in preclinical passive immunization studies, the classic AT8 pathological tau phosphorylation sites have remained understudied. Thus, we investigated the potential of immunotherapy against phosphorylated tau (pTau) in a P301S mouse model of tauopathy. We administered a new monoclonal B6 antibody that targets tau phosphorylation sites at serine 202, threonine 205 and serine 208 either systemically for 3 months or locally into the cerebral ventricles for 1 or 2 months via an osmotic minipump. Systemic administration failed to reach the brain effectively, and subsequently, was not able to alleviate the progressive motor impairment seen in this tauopathy mouse model. By contrast, intraventricular administration improved motor function in earlier stages of pathology but had a lesser effect in later stages. The local administration for 8 weeks reduced the number of pTau positive neurons in cortex and hippocampus. Our findings indicate that targeting the classical pathological tau phosphorylation sites can ameliorate tau pathology and improve function in a mouse tauopathy model. These results add to growing evidence supporting the efforts in developing tau-targeting immunotherapies for neurodegenerative diseases associated with pathological tau deposits., This research was funded by the European Union, Horizon 2020 project PANA, grant number 686009, Academy of Finland (grant numbers 338182, 307866, 315459, and 330178, 339767); the Sigrid Jusélius Foundation (SJ-2022) and the Strategic Neuroscience Funding of the University of Eastern Finland (NEURO-RC-2019). A.P-F.'s grant was funded by the European Union's FP7 Marie-Curie Initial Training Network program (grant agreement 606950). This study was also funded by grants from the Xunta de Galicia (IN607A2022/07), Instituto de Salud Carlos III (ISCIII) (PI22/00938, PI21/00727, CIBERNED CB22/05/00067, and RD21/0006/0005) and Ministerio de Ciencia e Innovación (RTC2019-007373-1 and PDC2022-134000-I00). Furthermore, this study was also supported by grants from the INTERREG Atlantic Area (EAPA_791/2018_NEUROATLANTIC project), INTER-REG V A España Portugal (POCTEP) (0624_2IQBIONEURO_6_E), and the European Regional Development Fund (ERDF). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer reviewed